Nanotechnological applications for the treatment of neurodegenerative disorders

Progress in Neurobiology

Volumn 88, Issue 4, 2009, Pages 272-285

  Modi, Girish ^a   Pillay, Viness ^a   Choonara, Yahya E ^a   Ndesendo, Valence M K ^a   du Toit, Lisa C ^a   Naidoo, Dinesh ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Alzheimer's disease; Biomaterials; Blood brain barrier; Nano enabled drug delivery systems; Nanotechnology; Neurodegenerative disorders; Parkinson's disease; Polymers; Targeted drug delivery

Indexed keywords

ANTINEOPLASTIC AGENT; BETA GALACTOSIDASE; CARBON NANOFIBER; CARBON NANOTUBE; CLIOQUINOL; ENBUCRILATE; FULLERENE; GOLD NANOPARTICLE; IMMUNOLIPOSOME; IRON OXIDE; NANOCAPSULE; NANOCARRIER; NANOGEL; NANOLIPOSOME; NANOPARTICLE; NANOSPHERE; NANOSUSPENSION; OLIGONUCLEOTIDE; PACLITAXEL; PENICILLAMINE; PLASMID DNA; QUINOLINE DERIVATIVE; SILICON DIOXIDE; THIOFLAVINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; DEGENERATIVE DISEASE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; DRUG TARGETING; DRUG TRANSPORT; GENETIC TRANSFECTION; GLIOSARCOMA; HUMAN; NANOMICELLE; NANOTECHNOLOGY; NERVE REGENERATION; NEUROPROTECTION; NEUROSCIENCE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OXIDATIVE STRESS; PARKINSON DISEASE; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; TISSUE ENGINEERING;

ALZHEIMER DISEASE; BIOCOMPATIBLE MATERIALS; BLOOD-BRAIN BARRIER; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NANOTECHNOLOGY; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE;

EID: 67650642274     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2009.05.002     Document Type: Review

References (131)

1. Alyaudtin R.N., Reichel A., Lobenberg R., Ramgel P., Kreuter J., and Begley D.J. Interaction of poly(butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro. J. Drug Target. 9 (2001) 209-221
2. Anderson W.F. Human gene therapy. Nature 392 (1998) 25-30
3. Barberi T., Klivenyi P., Calingasan N.Y., et al. Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in parkinsonian mice. Nat. Biotechnol. 21 (2003) 1200
4. Begley D.J. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol. Ther. 104 (2004) 29-45
5. Behan N., Birkinshaw C., and Clarke N. Poly n-butyl cyanoacrylate nanoparticles: a mechanistic study of polymerization and particle formation. Biomaterials 22 (2001) 1335-1344
6. Bensadoun J., Almeida L., Fine E.G., Tseng L., Deglon N., and Aebischer P. Comparative study of GDNF delivery systems for the CNS: polymer rods, encapsulated cells, and lentiviral vectors. J. Control. Release 87 1-3 (2003) 107-115
7. Betageri, G.V., 2004. US 6,759,058.
8. Bharali D.J., Klejbor I., Stachowiak E.K., Dutta P., Roy I., Kaur N., et al. Organically modified silica nanoparticles: a non-viral vector for in vivo gene delivery and expression in the brain. Proc. Natl. Acad. Sci. U.S.A. 102 32 (2005) 11539-11544
9. Blass J.P. Cerebrometabolic abnormalities in Alzheimer's disease. Neurol. Res. 25 6 (2003) 556-566
10. Bontha S., Kabanov A.V., and Bronich T.K. Polymer micelles with cross-linked ionic cores for delivery of anticancer drugs. J. Control. Release 114 (2006) 163-174
11. Borm P.J., and Kreyling W. Toxicological hazards of inhaled nanoparticles-potential implications for drug delivery. J. Nanosci. Nanotechnol. 4 (2004) 521-531
12. Brigger I., Morizet J., Aubert G., et al. Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting. J. Pharmacol. Exp. Ther. 303 (2002) 928-936
13. Bronich T.K., Bontha S., Shlyakhtenko L.S., Bromberg L., Hatton T.A., and Kabanov A.V. Template-assisted synthesis of nanogels from pluronic-modified poly(acrylic acid). J. Drug Target. 14 (2006) 357-366
14. Calvo P., Gouritin B., Chacun H., et al. Long-circulating pegylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm. Res. 18 (2001) 1157-1166
15. Calvo P., Gouritin B., Villarroya H., et al. Quantification and localization of pegylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat. Eur. J. Neurosci. 15 (2002) 1317-1326
16. Chang J.C., Brewer G.J., and Wheeler B.C. Modulation of neural network activity by patterning. Biosens. Bioelectron. 16 (2001) 527-533
17. Chekhonin V.P., Zhirkov Y.A., Gurina O.I., et al. Pegylated immunoliposomes directed against brain astrocytes. Drug Deliv. 12 (2005) 1-6
18. Chen Y.S., Hsieh C.L., Tsai C.C., et al. Peripheral nerve regeneration using silicone rubber chambers filled with collagen, laminin and fibronectin. Biomaterials 21 (2000) 1541-1547
19. Cherney R.A., Atwood C.S., Xilinas M.E., Gray D.N., Jones W.D., and McLean C.A. Treatment with a copper-zinc chelator markedly and rigidly inhibits B-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30 (2001) 665-676
20. Collister K.A., and Albensi B.C. Potential therapeutic targets in the NF-kappa-B pathway for Alzheimer's disease. Drug News Perspect. 18 (2005) 623-629
21. Cornford E.M., and Cornford M.E. New systems for delivery of drugs to the brain in neurological disease. Lancet Neurol. 1 (2002) 306-315
22. Cornish T., Branch D.W., Wheeler B.C., and Campanelli J.T. Microcontact printing: a versatile technique for the study of synaptogenic molecules. Mol. Cell Neurosci. 20 (2002) 140-153
23. Cui Z., Lockman P.R., Atwood C.S., et al. Novel d-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases. Eur. J. Pharm. Biopharm. 59 (2005) 263-272
24. Cui Z., Lockman P.R., Atwood C.S., et al. Novel d-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases. Eur. J. Pharmaceut. Biopharm. 59 (2005) 263-272
25. Dass B., and Kordower J.H. Gene therapy approaches for the treatment of Parkinson's disease. Handbook Clin. Neurol. 84 (2007) 291-304
26. Davis S.S. Biomedical applications of nanotechnology-implications for drug targeting and gene therapy. Trends Biotechnol. 15 6 (1997) 217-224
27. Dickson D.W. Misfolded, protease-resistant proteins in animal models and human neurodegenerative disease. J. Clin. Invest. 110 10 (2002) 1403-1405
28. Dong J., Atwood C., Anderson V., Siedlak S., Smith M., Perry G., and Carey P. Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: raman microscopic evidence. Biochemistry 42 (2003) 2768-2773
29. du Toit, L.C., Pillay, V., Choonara, Y.E., Pillay, S., Harillal, S., 2007. Patenting of nanopharmaceuticals in drug delivery: no small issue. Recent Patents Drug Deliv. Formulat. 1, 131-142.
30. Dugan L.L., Lovett E.G., and Quick K.L. Fullerene-based antioxidants and neurodegenerative disorders. Parkinsonism Relat. Disord. 7 3 (2001) 243-246
31. Dupas B., Berreur M., Rohanizadeh R., Bonnemain B., Meflah K., and Pradal G. Electron microscopy study of intrahepatic ultrasmall superparamagnetic iron oxide kinetics in the rat: relation with magnetic resonance imaging. Biol. Cell. 91 (1999) 195-208
32. Englund U., Bjorklund A., Wictorin K., Lindvall O., and Kokaia M. Grafted neural stem cells develop into functional pyramidal neurons and integrate into host cortical circuitry. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 17089-17094
33. Evans G.R. Challenges to nerve regeneration. Semin. Surf. Oncol. 19 (2000) 312-318
34. Fan Y.W., Cui F.Z., Hou S.P., Xu Q.Y., Chen L.N., and Lee I.S. Culture of neural cells on silicon wafers with nano-scale surface topograph. J. Neurosci. Methods 120 (2002) 17-23
35. Feng S.S., Mu L., Win K.Y., and Huang G. Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. Curr. Med. Chem. 11 (2004) 413-424
36. Ferri C.P., Prince M., Brayne C., et al. Global prevalence of dementia: a delphi consensus study. Lancet 366 9503 (2005) 2112-2117
37. Fiandaca M., Forsayeth J., and Bankiewicz K. Current status of gene therapy trials for Parkinson's disease. Exp. Neurol. 209 1 (2008) 51-57
38. Flachenecker P. Epidemiology of neuro-immunological diseases. J. Neurol. 253 (2006) 2-8
39. Freed C.R., Greene P.E., Breeze R.E., et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med. 344 (2001) 710-719
40. Friedrich I., Reichl S., and Muller-Goymann C.C. Drug release and permeation studies of nanosuspensions based on solidified reverse micellar solutions (SRMS). Int. J. Pharm. 305 (2005) 167-175
41. Friese A., Seiller E., Quack G., Lorenz B., and Kreuter J. Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system. Eur. J. Pharm. Biopharm. 49 (2000) 103-109
42. Fromherz P. Electrical interfacing of nerve cells and semiconductor chips. Chem. Phys. Chem. 3 3 (2002) 276-284
43. Gagliardi R.J. Neuroprotection, excito-toxicity and NMDA antagonists. Arq. Neuropsiquiatr. 58 (2000) 583-588
44. Gelperina S.E., Khalansky A.S., Skidan I.N., et al. Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma. Toxicol. Lett. 126 (2002) 131-141
45. Gosk S., Vermehren C., Storm G., and Moos T. Targeting anti-transferrin receptor antibody (OX26) and OX26-conjugated liposomes to brain capillary endothelial cells using in situ perfusion. J. Cereb. Blood Flow Metab. 24 (2004) 1193-1204
46. Gupta A.K., Berry C., Gupta M., and Curtis A. Receptor-mediated targeting of magnetic nanoparticles using insulin as a surface ligand to prevent endocytosis. IEEE Trans. Nanobiosci. 2 (2003) 255-261
47. Harada-Shiba M., Yamauchi K., Harada A., Takamisawa I., et al. Polyion complex micelles as vectors in gene therapy-pharmacokinetics and in vivo gene transfer. Gene Ther. 9 (2002) 407-414
48. Hartgerink J.D., Beniash E., and Stupp S.I. Peptide-amphiphile nanofibers: a versatile scaffold for the preparation of self-assembling materials. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 5133-5138
49. Hartgerink J.D., Beniash E., and Stupp S.I. Self-assembly and mineralization of peptide-amphiphile nanofibers. Science 294 (2001) 1684-1688
50. Hartig W., Paulke B., Varga C., Seeger J., Harkany T., and Kacza J. Electron microscopic analysis of nanoparticles delivering thioflavin-T after intrahippocampal injection in mouse: implications for targeting h-amyloid in Alzheimer's disease. Neurosci. Lett. 338 (2003) 174-176
51. Heck S., Qian X., and Velleca M. Genetically engineered mouse models for drug discovery: new chemical genetic approaches. Curr. Drug Discov. Technol. 1 1 (2004) 13-26
52. Hubbell J.A. Bioactive biomaterials. Curr. Opin. Biotechnol. 10 2 (1999) 123-129
53. Hyuk I.M.S., Jeong U., and Xia Y. Polymer hollow particles with controllable holes in their surfaces. Nat. Mater. 4 (2005) 671-675
54. Isacson O. The production and use of cells as therapeutic agents in neurodegenerative diseases. Lancet Neurol. 2 (2003) 417-424
55. Jin H., Chen W.Q., Tang X.W., Chiang L.Y., Yang C.Y., Schloss J.V., and Wu J.Y. Polyhydroxylated C (60), fullerenols, as glutamate receptor antagonists and neuroprotective agents. J. Neurosci. Res. 62 (2000) 600-607
56. Kabanov A.V., and Gendelman H.E. Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog. Polym. Sci. 32 8-9 (2007) 1054-1082
57. Kim J.H., Auerbach J.M., Rodríguez-Gómez J.A., et al. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature 418 (2002) 50-56
58. 12 cells for Parkinson's disease: a pre-clinical study in chronic MPTP-treated baboons. Neurobiol. Dis. 16 2 (2004) 428-439
59. Klejbor I., Stachowiak E.K., Bharali D.J., Roy I., Spodnik I., Morys J., Bergey E.J., Prasad P.N., and Stachowiak M.K. ORMOSIL nanoparticles as a non-viral gene delivery vector for modeling polyglutamine induced brain pathology. J. Neurosci. Methods 165 2 (2007) 230-243
60. Kogan M.J., Bastus N.G., Amigo, Grillo-Bosch R.D., Araya E., Turiel A., Labarta A., Giralt E., and Puntes V.F. Nanoparticle-mediated local and remote manipulation of protein aggregation. Nano Lett. 6 1 (2006) 110-115
61. Kreuter J., Alyautdin R., Kharkevich D., and Ivanov A. Passage of peptides through the blood-brain barrier with collodial polymer particles (nanoparticles). Brain Res. 674 (1995) 171-174
62. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev. 47 (2001) 65-81
63. Kreuter J., Shamenkov D., Petrov V., Ramge P., and Koch-Brandt C. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J. Drug Target. 10 (2002) 317-325
64. Kreuter J., Ramge P., Petrov V., et al. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm. Res. 20 (2003) 409-416
65. Kreuter J. Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain. J. Nanosci. Nanotechnol. 4 (2004) 484-488
66. Kumar R.M., Sameti M., et al. Polymeric nanoparticles for drug and gene delivery. In: Nalwa H.S. (Ed). Encyclopedia of Nanoscience & Nanotechnology (2003), American Scientific Publishers 1-19
67. Lauer L., Vogt A., Yeung C.K., Knoll W., and Offenhausser A. Electrophysiological recordings of patterned rat brain stem slice neurons. Biomaterials 23 (2002) 3123-3130
68. Liu C.Y., Apuzzo M.L., and Tirrell D.A. Engineering of the extracellular matrix: working toward neural stem cell programming and neurorestoration-concept and progress report. Neurosurgery 52 5 (2003) 1154-1165
69. Lockman P.R., Oyewumi M.O., Koziara J.M., Roder K.E., Mumper R.J., and Allen D.D. Brain uptake of thiamine-coated nanoparticles. J. Control. Release 93 (2003) 271-282
70. Lovell M., Robertson J., Teesadale W., Campbell J., and Markesbery W. Copper, iron and zinc in Alzheimer's disease senile plaques. J. Neurol. Sci. 158 (1998) 47-52
71. Luo D., and Saltzman W.M. Synthetic DNA delivery systems. Nat. Biotechnol. 18 1 (2000) 33-37
72. Ma S.H., Lepak L.A., Hussain R.J., Shain W., and Shuler M.L. An endothelial and astrocyte co-culture model of the blood-brain barrier utilizing an ultra-thin, nanofabricated silicon nitride membrane. Lab Chip 5 (2005) 74-85
73. Mahadik S.P., and Mukherjee S. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr. Res. 19 (1996) 1-17
74. Mandel S.A., Amit T., Machluf M., and Youdim M.B.H. Nanoparticles: a step forward for iron chelation in the brain. Future Neurol. 2 3 (2007) 265-269
75. Massia S.P., and Hubbell J.A. An RGD spacing of 440 nm is sufficient for integrin avb3-mediated fibroblast spreading and 140 nm for local contact and stress fiber formation. J. Cell Biol. 114 (1991) 1089-1100
76. Massia S.P., Rao S., and Hubbell J.A. Covalently immobilized laminin peptide Tyr-LIe-Gly-Ser-Arg (YIGSR) supports cell spreading and colocalization of the 67-kilodalton laminin receptor with alpha-actinin and vinculin. J. Biol. Chem. 268 (1993) 8053-8059
77. McAllister K., Sazani P., Adam M., et al. Polymeric nanogels produced via inverse microemulsion polymerization as potential gene and antisense delivery agents. J. Am. Chem. Soc. 124 (2002) 15198-15207
78. McArthur J.C. HIV dementia: an evolving disease. J. Neuroimmunol. 157 (2004) 3-10
79. McKenzie J.L., Waid M.C., Shi R., and Webster T.J. Decreased functions of astrocytes on carbon nanofiber materials. Biomaterials 25 (2004) 1309-1317
80. McKerlie C. Cause and effect considerations in diagnostic pathology and pathology phenotyping of genetically engineered mice (GEM). ILAR J. 47 2 (2006) 156-162
81. Menei P., Montero-Menei C., Venier M.C., and Benoit J.P. Drug delivery into the brain using poly(lactide-co-glycolide) microspheres. Expert Opin. Drug Deliv. 2 (2005) 363-376
82. Miller G. Drug targeting: breaking down barriers. Science 297 (2002) 1116-1118
83. Mora M., Sagristá M.L., Trombetta D., Bonina F.P., De Pasquale A., and Saija A. Design and characterization of liposomes containing long-chain N-acylpes for brain delivery: penetration of liposomes incorporating GM1 into the rat brain. Pharm. Res. 19 (2002) 1430-1438
84. Muller R.H., and Keck C.M. Drug delivery to the brain-realization by novel drug carriers. J. Nanosci. Nanotechnol. 4 (2004) 471-483
85. Nguyen H.K., Lemieux P., Vinogradov S.V., et al. Evaluation of polyether-polyethyleneimine graft copolymers as gene transfer agents. Gene Ther. 7 (2000) 126-138
86. Niece K.L., Hartgerink J.D., Donners J.J., and Stupp S.I. Self-assembly combining two bioactive peptide-amphiphile molecules into nanofibers by electrostatic attraction. J. Am. Chem. Soc. 125 (2003) 7146-7147
87. Oishi M., Hayashi H., Iijima M., and Nagasaki Y. Endosomal release and intracellular delivery of anticancer drugs using pH-sensitive pegylated nanogels. J. Mater. Chem. 17 (2007) 3720-3725
88. Olmedo I., Araya E., Sanz F., Medina E., Arbiol J., Toledo P., Álvarez-Lueje A., Giralt E., and Kogan M.J. How changes in the sequence of the peptide CLPFFD-NH2 can modify the conjugation and stability of gold nanoparticles and their affinity for beta-amyloid fibrils. Bioconjugate Chem. 19 6 (2008) 1154-1163
89. Parati E.A., Bez A., Ponti D., Sala S., Pozzi S., and Pagano S.F. Neural stem cells. biological features and therapeutic potential in Parkinson's disease. J. Neurosurg. Sci. 47 (2003) 8-17
90. Pardridge W. Drug and gene delivery to the brain: the vascular route. Neuron 36 (2002) 555-558
91. Pardridge W.M. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2 (2005) 3-14
92. Peira E., Marzola P., Podio V., Aime S., Sbarbati A., and Gasco M.R. In vitro and in vivo study of solid lipid nanoparticles loaded with superparamagnetic iron oxide. J. Drug Target. 11 (2003) 19-24
93. Piccini P., Lindvall O., Björklund A., et al. Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Ann. Neurol. 48 (2000) 689-695
94. Pollak P., Fraix V., Krack P., et al. Treatment results: Parkinson's disease. Mov. Disord. 17 (2002) 75-83
95. Popovic N., and Brundin P. Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases. Int. J. Pharm. 314 2 (2006) 120-126
96. Powell S.K., Rao J., Roque E., et al. Neural cell response to multiple novel sites on laminin-1. J. Neurosci. Res. 61 (2000) 302
97. Prasad P.N. Introduction to Biophotonics (2003), John Wiley and Sons, Inc., Hoboken, NJ
98. Prasad P.N. Nanophotonics (2004), John Wiley and Sons, Inc., Hoboken, NJ
99. Raghupathi R., Graham D.I., and McIntosh T.K. Apoptosis after traumatic brain injury. J. Neurotrauma. 17 (2000) 927-938
100. Ritchie C.W., Bush A.I., and Masters C.L. Metal-protein attenuating compounds and Alzheimer's disease. Expert Opin. Invest. Drugs 13 12 (2004) 1585-1592
101. Roney C., Kulkarn P., Arora V., et al. Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease. J Control. Release 108 (2005) 193-214
102. Roy I., Ohulchanskyy T.Y., Bharali D.J., Pudavar H.E., Mistretta R.A., Kaur N., et al. Optical tracking of organically modified silica nanoparticles as DNA carriers: a nonviral, nanomedicine approach for gene delivery. Proc. Natl. Acad. Sci. U.S.A. 102 2 (2005) 279-284
103. Rzigalinski B.A., Meehan K., and Davis R.M. Radical nanomedicine. Nanomedicine 1 4 (2006) 399-412
104. Schmidt J., Metselaar J.M., Wauben M.H.M., Toyka K.V., Storm G., and Gold R. Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain 126 (2003) 1895-1904
105. Service R.F. American Chemical Society meeting: molecular scaffolding helps raise a crop of neurons. Science 302 (2003) 46-47
106. Shi N., Zhang W., Zhu C., Boado R.J., and Pardridge W.M. Brain-specific expression of an exogenous gene after i.v. administration. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 12754-12759
107. Siepmann J., and Editor T. Local controlled drug delivery to the brain. Int. J. Pharm. 314 2 (2006) 99-100
108. Silva G.A. Nanotechnology approaches for the regeneration and neuroprotection of the central nervous system. Surg. Neurol. 63 4 (2005) 301-306
109. Silva G.A., Czeisler C., Niece K.L., et al. Selective differentiation of neural progenitor cells by high-epitope density nanofibers. Science 303 (2004) 1352-1355
110. Silva G.A., Czeisler C., Niece K.L., et al. Development of neural progenitor cells encapsulated in a peptide amphiphile substrate that is induced to self-assemble under physiological conditions. Presented at: Annual Meeting of the Society for Neuroscience. Orlando, FL, USA, November 2-7 (2002)
111. Silva G.A., Kehl K., Niece K.L., and Stupp S.I. Nanoengineered peptide amphiphile network for photoreceptor replacement in degenerative retinal disorders. Assoc. Res. Vis. Ophthalmol. Abstr. (2003)
112. Singh N., Pillay V., and Choonara Y.E. Advances in the treatment of Parkinson's disease. Prog. Neurobiol. 81 (2007) 29-44
113. Steiniger S.C., Kreuter J., Khalansky A.S., et al. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int. J. Cancer 109 (2004) 759-767
114. Suk J.S., Suh J., and Choy K. Gene delivery to differentiated neurotypic cells with RGD and HIV tat peptide functionalized polymeric nanoparticles. Biomaterials 27 29 (2006) 5143-5150
115. Thiebaud P., Lauer L., Knoll W., and Offenhausser A. PDMS device for patterned application of microfluids to neuronal cells arranged by microcontact printing. Biosens. Bioelectron. 17 (2002) 87-93
116. Torchilin V.P. Peg-based micelles as carriers of contrast agents for different imaging modalities. Adv. Drug Deliv. Rev. 54 (2002) 235-252
117. Torchilin V.P. Targeted polymeric micelles for delivery of poorly soluble drugs. Cell Mol. Life Sci. 61 (2004) 2549-2559
118. Tyler C.M., and Federoff H.J. CNS gene therapy and a nexus of complexity: systems and biology at a crossroads. Cell Transplant. 15 (2006) 267-273
119. Vauthier C., Dubernet C., Chauvierre C., Brigger I., and Couvreur P. Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles. J. Control. Release 93 (2003) 151-160
120. Verma A. Opportunities for neuroprotection in traumatic brain injury. J. Head Trauma Rehabil. 15 (2000) 1149-1161
121. Vinogradov S.V., Zeman A.D., Batrakova E.V., and Kabanov A.V. Polyplex nanogel formulations for drug delivery of cytotoxic nucleoside analogs. J. Control. Release 107 (2005) 143-157
122. Voinea M., and Simionescu M. Designing of 'intelligent' liposomes for efficient delivery of drugs. J. Cell Mol. Med. 6 (2002) 465-474
123. Wang F., Bronich T.K., Kabanov A.V., Rauh R.D., and Roovers J. Synthesis and evaluation of a star amphiphilic block copolymer from poly(epsilon-caprolactone) and poly(ethylene glycol) as a potential drug delivery carrier. Bioconjugate Chem. 16 (2005) 397-405
124. Webster T.J., Waid M.C., McKenzie J.L., Price R.L., and Ejiofor J.U. Nano-biotechnology: carbon nanofibres as improved neural and orthopedic implants. Nanotechnology 15 1 (2004) 48-54
125. William G.J. Late-onset neurodegenerative diseases-the role of protein insolubility. J. Anat. 196 4 (2000) 609-616
126. Wilson J.X., and Gelb A.W. Free radicals, antioxidants, and neurologic injury: possible relationship to cerebral protection by anesthetics. J. Neurosurg. Anesthesiol. 14 (2002) 66-79
127. Woo S.H. Evidence of a pluripotent human embryonic stem cell line derived from a cloned blastocyst. Science 303 (2004) 1669-1674
128. Woodruff B.K., Graff-Radford N.R., and Ferman T.J. Family history of dementia is a risk factor for Lewy body disease. Neurology 66 12 (2006) 1949-1950
129. Yeung C.K., Lauer L., Offenhausser A., and Knoll W. Modulation of the growth and guidance of rat brain stem neurons using patterned extracellular matrix proteins. Neurosci. Lett. 301 (2001) 147-150
130. Zhang X., Prasad S., Niyogi S., Morgan A., Ozkan M., and Ozkan C.S. Guided neurite growth on patterned carbon nanotubes. Sens. Actuators B: Chem. 106 (2005) 843-850
131. Zhou H., Gupta A., Zou T., and Zhou J. Photoresist derived carbon for growth and differentiation of neural cells. Int. J. Mol. Sci. 8 (2007) 884-893